Botanix Pharmaceuticals to Not Rely Upon ASX Partial Waiver After Verifying Sufficient Securities Under its Placement Capacity
MT Newswires Live
Oct 21, 2025
Botanix Pharmaceuticals (ASX:BOT) said it would not rely upon a partial waiver granted by the ASX after it verified that the securities under its current placement capacity are sufficient to meet its obligations in relation to an earlier loan facility, according to a Tuesday Australian bourse filing.
Botanix and its wholly-owned unit, Botanix Pharmaceuticals Inc., entered into documentation with Kreos Capital VII (UK) and related entities for a loan facility of up to $30 million.
The ASX had partially granted it a waiver of listing rules to allow the firm to seek shareholder approval at its annual general meeting for the ratification of the agreement to issue securities under the facility, so that those securities would not take up its placement capacity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.